Loading...

Evgen Pharma

DB:8EV
Snowflake Description

Adequate balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
8EV
DB
£20M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Evgen Pharma plc, a clinical stage drug development company, focuses on the treatment of cancer and neurological diseases. The last earnings update was 127 days ago. More info.


Add to Portfolio Compare Print
  • Evgen Pharma has significant price volatility in the past 3 months.
8EV Share Price and Events
7 Day Returns
11.6%
DB:8EV
-0.7%
DE Biotechs
2.5%
DE Market
1 Year Returns
-
DB:8EV
-9.2%
DE Biotechs
-6.7%
DE Market
8EV Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Evgen Pharma (8EV) 11.6% 16.5% 28.5% - - -
DE Biotechs -0.7% 4.7% -6.2% -9.2% 44% 8.7%
DE Market 2.5% 3.3% 9.2% -6.7% 9% 13.5%
1 Year Return vs Industry and Market
  • No trading data on 8EV.
  • No trading data on 8EV.
Price Volatility
8EV
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Evgen Pharma undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Evgen Pharma. This is due to cash flow or dividend data being unavailable. The share price is €0.212.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Evgen Pharma's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Evgen Pharma's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:8EV PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-09-30) in GBP £-0.03
AIM:EVG Share Price ** AIM (2019-04-18) in GBP £0.2
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.53x
Germany Market PE Ratio Median Figure of 421 Publicly-Listed Companies 19.69x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Evgen Pharma.

DB:8EV PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= AIM:EVG Share Price ÷ EPS (both in GBP)

= 0.2 ÷ -0.03

-6.5x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Evgen Pharma is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Evgen Pharma is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Evgen Pharma's expected growth come at a high price?
Raw Data
DB:8EV PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -6.5x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
-1.3%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.31x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Evgen Pharma, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Evgen Pharma's assets?
Raw Data
DB:8EV PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-09-30) in GBP £0.02
AIM:EVG Share Price * AIM (2019-04-18) in GBP £0.2
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.85x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.87x
DB:8EV PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= AIM:EVG Share Price ÷ Book Value per Share (both in GBP)

= 0.2 ÷ 0.02

8.58x

* Primary Listing of Evgen Pharma.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Evgen Pharma is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Evgen Pharma's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Evgen Pharma has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Evgen Pharma expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-1.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Evgen Pharma expected to grow at an attractive rate?
  • Unable to compare Evgen Pharma's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Evgen Pharma's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Unable to compare Evgen Pharma's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:8EV Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:8EV Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts -1.3%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.4%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.7%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:8EV Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in GBP Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:8EV Future Estimates Data
Date (Data in GBP Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2022-03-31 0 -3 -3 1
2021-03-31 0 -3 -3 1
2020-03-31 0 -3 -3 1
2019-03-31 0 -3 -3 1
DB:8EV Past Financials Data
Date (Data in GBP Millions) Revenue Cash Flow Net Income *
2018-09-30 -2 -3
2018-06-30 -2 -3
2018-03-31 -2 -3
2017-12-31 -3 -3
2017-09-30 -3 -3
2017-06-30 -3 -3
2017-03-31 -3 -3
2016-12-31 -3 -3
2016-09-30 -3 -4
2016-06-30 -2 -3
2016-03-31 -2 -3
2015-12-31 -1 -3

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Evgen Pharma is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Unable to determine if Evgen Pharma is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:8EV Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Evgen Pharma Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:8EV Future Estimates Data
Date (Data in GBP Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2022-03-31 -0.02 -0.02 -0.02 1.00
2021-03-31 -0.02 -0.02 -0.02 1.00
2020-03-31 -0.03 -0.03 -0.03 1.00
2019-03-31 -0.03 -0.03 -0.03 1.00
DB:8EV Past Financials Data
Date (Data in GBP Millions) EPS *
2018-09-30 -0.03
2018-06-30 -0.03
2018-03-31 -0.03
2017-12-31 -0.04
2017-09-30 -0.04
2017-06-30 -0.04
2017-03-31 -0.04
2016-12-31 -0.05
2016-09-30 -0.05
2016-06-30 -0.06
2016-03-31 -0.06
2015-12-31 -0.07

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Evgen Pharma will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Evgen Pharma's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Evgen Pharma has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Evgen Pharma performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Evgen Pharma's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Evgen Pharma does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Evgen Pharma's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Evgen Pharma's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Evgen Pharma's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Evgen Pharma Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:8EV Past Revenue, Cash Flow and Net Income Data
Date (Data in GBP Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-09-30 -2.69 3.13
2018-06-30 -2.64 3.08
2018-03-31 -2.58 3.03
2017-12-31 -2.82 3.34
2017-09-30 -3.06 3.65
2017-06-30 -3.07 3.65
2017-03-31 -3.07 3.66
2016-12-31 -3.35 3.30
2016-09-30 -3.63 2.94
2016-06-30 -3.38 2.34
2016-03-31 -3.13 1.75
2015-12-31 -2.73 1.38
2015-09-30 -2.33 1.01
2015-06-30 -2.30 0.98
2015-03-31 -2.27 0.95
2014-03-31 -1.08 0.38 0.50
2013-03-31 -0.87 0.34 0.61

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Evgen Pharma has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Evgen Pharma has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Evgen Pharma improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Evgen Pharma's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Evgen Pharma has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Evgen Pharma's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Evgen Pharma's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Evgen Pharma is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Evgen Pharma has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Evgen Pharma's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Evgen Pharma has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Evgen Pharma Company Filings, last reported 6 months ago.

DB:8EV Past Debt and Equity Data
Date (Data in GBP Millions) Total Equity Total Debt Cash & Short Term Investments
2018-09-30 2.15 0.00 2.16
2018-06-30 2.15 0.00 2.16
2018-03-31 3.87 0.00 3.63
2017-12-31 3.87 0.00 3.63
2017-09-30 2.63 0.00 2.21
2017-06-30 2.63 0.00 2.21
2017-03-31 4.23 0.00 3.86
2016-12-31 4.23 0.00 3.86
2016-09-30 5.50 0.00 5.55
2016-06-30 5.50 0.00 5.55
2016-03-31 7.09 0.00 7.13
2015-12-31 7.09 0.00 7.13
2015-09-30 -0.36 1.65 1.78
2015-06-30 -0.36 1.65 1.78
2015-03-31 -1.19 1.07 0.16
2014-03-31 0.18 0.15 0.31
2013-03-31 0.18 0.00 0.11
  • Evgen Pharma has no debt.
  • Evgen Pharma has no debt compared to 5 years ago when it was 42.9%.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Evgen Pharma has less than a year of cash runway based on current free cash flow.
  • Evgen Pharma has less than a year of cash runway if free cash flow continues to grow at historical rates of 15.6% each year.
X
Financial health checks
We assess Evgen Pharma's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Evgen Pharma has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Evgen Pharma's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Evgen Pharma dividends.
If you bought €2,000 of Evgen Pharma shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Evgen Pharma's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Evgen Pharma's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:8EV Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 324 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:8EV Future Dividends Estimate Data
Date (Data in £) Dividend per Share (annual) Avg. No. Analysts
2022-03-31
2021-03-31
2020-03-31
2019-03-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Evgen Pharma has not reported any payouts.
  • Unable to verify if Evgen Pharma's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Evgen Pharma's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Evgen Pharma has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Evgen Pharma's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Evgen Pharma afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Evgen Pharma has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Evgen Pharma's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Steve Franklin
COMPENSATION £214,602
CEO Bio

Dr. Stephen J. Franklin, also known as Steve, serves Chief Executive Officer of Evgen Pharma Plc. He has been an Executive Director at Evgen Pharma plc since October 2, 2014. He has over 20 years’ commercial experience in life science industries, focusing on the commercialisation of new technology. Dr. Franklin served as Chief Executive Officer of Provexis plc (formerly Provexis Limited) until June 2006 and its Acting Director of Research from July 24, 2006 to July 24, 2006. Prior to this, he was a Principal Executive with the ANGLE Technology Group where he was intimately involved in establishing its Life Science Venture business unit and the regional office in the North West of England. He served as an Executive Director of Provexis plc from June 23, 2005 to July 24, 2006. He founded and mentored a number of new life science ventures. He has a B.Sc. in Biology from York university, a PhD in Applied Biochemistry from Nottingham and an MBA with distinction also from Nottingham.

CEO Compensation
  • Steve's compensation has been consistent with company performance over the past year.
  • Steve's remuneration is about average for companies of similar size in Germany.
Management Team Tenure

Average tenure of the Evgen Pharma management team in years:

1.7
Average Tenure
  • The average tenure for the Evgen Pharma management team is less than 2 years, this suggests a new team.
Management Team

Steve Franklin

TITLE
CEO & Executive Director
COMPENSATION
£215K

Richard Moulson

TITLE
CFO & Executive Director
COMPENSATION
£94K
AGE
56
TENURE
2.1 yrs

Liz Jenkins

TITLE
Regulatory Consultant

Tom Morris

TITLE
Consultant & Medical Advisor of Oncology
TENURE
2.1 yrs

Albena Dinkova-Kostova

TITLE
Independent Scientific Advisor
TENURE
1.3 yrs

Giovanni Mann

TITLE
Independent Scientific Advisor
TENURE
1.3 yrs
Board of Directors Tenure

Average tenure and age of the Evgen Pharma board of directors in years:

2.3
Average Tenure
60.5
Average Age
  • The average tenure for the Evgen Pharma board of directors is less than 3 years, this suggests a new board.
Board of Directors

Barry Clare

TITLE
Non-Executive Chairman
COMPENSATION
£35K
AGE
65
TENURE
2.3 yrs

Steve Franklin

TITLE
CEO & Executive Director
COMPENSATION
£215K
TENURE
4.5 yrs

Richard Moulson

TITLE
CFO & Executive Director
COMPENSATION
£94K
AGE
56
TENURE
2.3 yrs

Sue Foden

TITLE
Senior Independent Director
COMPENSATION
£27K
AGE
65

Alan Barge

TITLE
Non-Executive Director
COMPENSATION
£23K
TENURE
3.5 yrs

Susan Clement-Davies

TITLE
Non-Executive Director
AGE
56
TENURE
0.4 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Evgen Pharma's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Evgen Pharma has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Evgen Pharma plc, a clinical stage drug development company, focuses on the treatment of cancer and neurological diseases. Its core technology is Sulforadex, which include synthetic and stabilized analogues of the naturally occurring compound sulforaphane. The company’s lead product is SFX-01, a synthetic version of sulforaphane stabilised that is in Phase II clinical trials for the treatment of breast cancer and subarachnoid haemorrhage, as well as in preclinical stage for multiple sclerosis and clinical stage to treat prostate cancer. Evgen Pharma plc was founded in 2007 and is headquartered in Wilmslow, the United Kingdom.

Details
Name: Evgen Pharma plc
8EV
Exchange: DB
Founded: 2007
£22,619,233
98,991,334
Website: http://www.evgen.com
Address: Evgen Pharma plc
The Colony,
Altrincham Road,
Wilmslow,
Cheshire, SK9 4LY,
United Kingdom
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
AIM EVG Ordinary Shares London Stock Exchange AIM Market GB GBP 21. Oct 2015
DB 8EV Ordinary Shares Deutsche Boerse AG DE EUR 21. Oct 2015
Number of employees
Current staff
Staff numbers
11
Evgen Pharma employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/18 22:51
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/18
Last earnings filing: 2018/12/12
Last earnings reported: 2018/09/30
Last annual earnings reported: 2018/03/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.